drugset / Trial / NCT00941369

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

NCT00941369

Phase 4 Completed 345 enrolled Sanofi
RandomizedCrossoverOpen-labelTreatment

Summary

Primary Objective: To investigate the impact of insulin glargine versus Neutral Protamine Hagedorn basal insulin on a composite diabetes related quality of life score (DRQoL). Secondary Objective: A comparison of combination therapy with insulin glargine versus Neutral Protamine Hagedorn basal insulin from baseline to endpoint in terms of: * Glycaemic parameters: 7 blood glucose profiles * Incidence of confirmed symptomatic hypoglycemia as well as confirmed severe hypoglycemia * Change in lipid status

Timeline

Start
2009-06
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 10 iu Subcutaneous
Subject insulin glargine Protein / enzyme biologic 10 iu Subcutaneous